IGC

IGC Pharma Inc. (IGC) | Rumor.io

IGC Pharma

IGC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,528

Bullish sentiment (50-day avg)94%

Price to earnings ratio-3.05

Market capitalization27.9M

Earnings per share-0.06

Dividend yield (TTM)26.9%

Revenue (annual)1.3M

Net income (annual)-7.1M

Social

What share of all stock conversation is about IGC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% +0	0% 0

Aug 27

India Globalization Capital, Inc. ($IGC) is experiencing pre-market volume, with some analysts speculating it could take off.
The company's phase 2 Calma trial for Alzheimer's is due to start in Q4, and the CEO and Financial Officer have recently purchased 4.3 million shares of restricted common stock at $0.27.
Ascendient Capital has raised its price target for India Globalization Capital, Inc. to $6.00 USD, and the company is getting close to full patient enrollment on phase II.

Generated by AI

Sentiment

Of the messages about IGC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% +6.44	79.76% -9.58
Bearish	0% 0	0%	0% -6.44	20.24% +9.58

Bullish· Aug 27

The company's CEO and Financial Officer purchased 4.3 million shares of restricted common stock at $0.27, demonstrating their conviction in the company's future.
Ascendient Capital has continuously raised their price target for IGC, most recently from $5.50 to $6.00 USD, indicating their confidence in the company's growth potential.
The company is getting close to full patient enrollment on phase II of its Calma trial for Alzheimer's, which could lead to significant news and potential price appreciation.

Bearish· Apr 20

$IGC has been stuck at $0.30 for several years, suggesting a lack of upward momentum.
The company's major shareholders are likely to take a significant loss, indicating a bearish sentiment.
The stock's price is likely to dilute due to future offerings, which could further depress the value.

Generated by AI

Topics

Of the messages about IGC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	67.91%
Technical Analysis	0%	0%	0%	14.33%
Analysts	0%	0%	0%	10.89%
Earnings	0%	0%	0%	0.86%
Controversies	0%	0%	0%	6.02%
Macro	0%	0%	0%	0%

Earnings· Feb 20

India Globalization Capital, Inc. ($IGC) reports Q3 financial results with an EPS loss of $0.02.
$IGC's earnings report is expected to be released after hours today.
Investors are awaiting $IGC's earnings report with questions and expectations.

Announcements· Apr 20

IGC Pharma has secured psilocybin research authorization in Colombia, allowing it to explore the compound for neuropsychiatric symptoms in dementia patients.
The company has expanded its focus on neuropsychiatric symptoms in dementia, with its Phase 2 CALMA trial for IGC-AD1 reaching 80% enrollment.
IGC Pharma has secured North American composition protection (patents) for IGC-AD1, strengthening its competitive position and potential for future commercialization.

Controversies· Apr 26

India Globalization Capital, Inc. (IGC) has submitted international patent applications for IGC-501.
IGC's patent applications for IGC-501 are pending review by international authorities.
The patent applications for IGC-501 may be related to the company's potential for future revenue or growth.

Technical Analysis· Jul 23

$IGC is in a buy range and has bottomed out, with bulls accumulating and shorts being trapped.
A cup and handle bullish pattern has formed, with a potential first bounce target at $3.60 and a possible breakout above.
$IGC has broken a downward trend line and may be setting up for a mini squeeze, with momentum looking bullish for the open.

Generated by AI

Community

Of the messages about IGC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	32.08%	49.33%	20.12%	29.99%
Newcomers	67.92%	50.67%	79.88%	70.01%

Regulars· Aug 14

The regulars are watching for a clean break and hold above $0.3098, which would strengthen the consolidation thesis and potentially lead to a bigger move.
The company has reached a clinical milestone in its Phase 2 CALMA trial, which is a first in its history, and a successful readout could fundamentally change how the market values the company.
The 15-min chart shows a high-volume breakout from the $0.24–$0.25 base, followed by higher lows and solid support around $0.275–$0.28, with price holding above key EMAs/VWAP and classic accumulation and momentum building ahead of the Phase 2 catalyst.

Newcomers· Aug 27

Newcomers are excited about the potential for a significant increase in the stock price, with some predicting a return of 500-2000%.
There is speculation about a potential pullback in the stock price, with some users expecting a sell-off, but others remain optimistic about the company's future prospects.
Users are tracking the stock's volume, with some noticing a large block of shares being bought and others expecting a significant increase in volume to be a sign of the stock's potential.

Generated by AI

News

IGC Pharma earnings matched, revenue fell short of estimates

1mo agoInvesting.com

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Detailed price information for Igc Pharma Inc (IGC-A) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, ...

1mo agoYahoo Finance

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

POTOMAC, MD/ ACCESS Newswire/ July 29, 2026/ IGC Pharma, Inc., a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24- CR-456, in the United States District Court for the Central District of...

2mo agoNasdaq

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS Newswire / July 9, 2026 / ...

2mo agoYahoo Finance

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE ...

2mo agoYahoo Finance

Also Discussed

Investors talking about IGC also mention

#	Name	Attention
1	Oragenics Inc.OGEN	0%0
2	Cronos Group Inc.CRON	0%0
3	CorMedix Inc.CRMD	0%+0
4	Planet Green Holdings Corp.PLAG	0%new
5	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
6	22nd Century Group Inc.XXII	0%0
7	Avalon Holdings Corp. Class A Common StockAWX	0%new
8	Arcadia Biosciences Inc.RKDA	0.01%0
9	Canopy Growth CorporationCGC	0%-0.01
10	Tilray Brands Inc.TLRY	0.02%0

IGC Pharma Inc.

Healthcare
Biotechnology

IGC Pharma Inc. is a pharmaceutical and biotechnology company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, cancer, and other life-altering conditions. The company's primary role involves leveraging unique approaches to drug development, particularly using cannabinoids, to create novel solutions that address unmet medical needs. IGC Pharma operates within the biotech sector, which is marked by significant research and development activities and a robust pipeline of products at various stages of clinical trials. Notably, IGC Pharma's initiatives in the pharmaceutical industry aim at integrating traditional pharmaceutical methods with new advancements in cannabinoid science. This positions the company as a potential influencer in sectors such as pain management and oncology, where treatment options are continually evolving. Due to its focus on strategic research and development, IGC Pharma plays a crucial role in the broader biotechnology market, aiming to introduce cutting-edge therapies that can change the standard of care for complex medical conditions.

Website

Location

10224 Falls Road

Potomac, MD, 20854

United States

Social

What share of all stock conversation is about IGC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% +0	0% 0

Aug 27

India Globalization Capital, Inc. ($IGC) is experiencing pre-market volume, with some analysts speculating it could take off.
The company's phase 2 Calma trial for Alzheimer's is due to start in Q4, and the CEO and Financial Officer have recently purchased 4.3 million shares of restricted common stock at $0.27.
Ascendient Capital has raised its price target for India Globalization Capital, Inc. to $6.00 USD, and the company is getting close to full patient enrollment on phase II.

Generated by AI

Sentiment

Of the messages about IGC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% +6.44	79.76% -9.58
Bearish	0% 0	0%	0% -6.44	20.24% +9.58

Bullish· Aug 27

The company's CEO and Financial Officer purchased 4.3 million shares of restricted common stock at $0.27, demonstrating their conviction in the company's future.
Ascendient Capital has continuously raised their price target for IGC, most recently from $5.50 to $6.00 USD, indicating their confidence in the company's growth potential.
The company is getting close to full patient enrollment on phase II of its Calma trial for Alzheimer's, which could lead to significant news and potential price appreciation.

Bearish· Apr 20

$IGC has been stuck at $0.30 for several years, suggesting a lack of upward momentum.
The company's major shareholders are likely to take a significant loss, indicating a bearish sentiment.
The stock's price is likely to dilute due to future offerings, which could further depress the value.

Generated by AI

Topics

Of the messages about IGC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	67.91%
Technical Analysis	0%	0%	0%	14.33%
Analysts	0%	0%	0%	10.89%
Earnings	0%	0%	0%	0.86%
Controversies	0%	0%	0%	6.02%
Macro	0%	0%	0%	0%

Earnings· Feb 20

India Globalization Capital, Inc. ($IGC) reports Q3 financial results with an EPS loss of $0.02.
$IGC's earnings report is expected to be released after hours today.
Investors are awaiting $IGC's earnings report with questions and expectations.

Announcements· Apr 20

IGC Pharma has secured psilocybin research authorization in Colombia, allowing it to explore the compound for neuropsychiatric symptoms in dementia patients.
The company has expanded its focus on neuropsychiatric symptoms in dementia, with its Phase 2 CALMA trial for IGC-AD1 reaching 80% enrollment.
IGC Pharma has secured North American composition protection (patents) for IGC-AD1, strengthening its competitive position and potential for future commercialization.

Controversies· Apr 26

India Globalization Capital, Inc. (IGC) has submitted international patent applications for IGC-501.
IGC's patent applications for IGC-501 are pending review by international authorities.
The patent applications for IGC-501 may be related to the company's potential for future revenue or growth.

Technical Analysis· Jul 23

$IGC is in a buy range and has bottomed out, with bulls accumulating and shorts being trapped.
A cup and handle bullish pattern has formed, with a potential first bounce target at $3.60 and a possible breakout above.
$IGC has broken a downward trend line and may be setting up for a mini squeeze, with momentum looking bullish for the open.

Generated by AI

Community

Of the messages about IGC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	32.08%	49.33%	20.12%	29.99%
Newcomers	67.92%	50.67%	79.88%	70.01%

Regulars· Aug 14

The regulars are watching for a clean break and hold above $0.3098, which would strengthen the consolidation thesis and potentially lead to a bigger move.
The company has reached a clinical milestone in its Phase 2 CALMA trial, which is a first in its history, and a successful readout could fundamentally change how the market values the company.
The 15-min chart shows a high-volume breakout from the $0.24–$0.25 base, followed by higher lows and solid support around $0.275–$0.28, with price holding above key EMAs/VWAP and classic accumulation and momentum building ahead of the Phase 2 catalyst.

Newcomers· Aug 27

Newcomers are excited about the potential for a significant increase in the stock price, with some predicting a return of 500-2000%.
There is speculation about a potential pullback in the stock price, with some users expecting a sell-off, but others remain optimistic about the company's future prospects.
Users are tracking the stock's volume, with some noticing a large block of shares being bought and others expecting a significant increase in volume to be a sign of the stock's potential.

Generated by AI

IGC Pharma

Social

Aug 27

Bullish· Aug 27

Bearish· Apr 20

Earnings· Feb 20

Announcements· Apr 20

Controversies· Apr 26

Technical Analysis· Jul 23

Regulars· Aug 14

Newcomers· Aug 27

IGC Pharma earnings matched, revenue fell short of estimates

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Also Discussed

IGC Pharma Inc.

Company Information

Location

IGC Pharma earnings matched, revenue fell short of estimates

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Also Discussed

Social

Aug 27

Bullish· Aug 27

Bearish· Apr 20

Earnings· Feb 20

Announcements· Apr 20

Controversies· Apr 26

Technical Analysis· Jul 23

Regulars· Aug 14

Newcomers· Aug 27